The current state of randomized clinical trial evidence for prostate brachytherapy.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
09 2019
Historique:
received: 30 10 2018
revised: 26 03 2019
accepted: 09 04 2019
pubmed: 8 5 2019
medline: 12 9 2020
entrez: 8 5 2019
Statut: ppublish

Résumé

Interstitial brachytherapy is one of several curative therapeutic options for the treatment of localized prostate cancer. In this review, we summarize all available randomized data to support the optimal use of prostate brachytherapy. Evidence from completed randomized controlled trials is the focus of this review with a presentation also of important ongoing trials. Gaps in knowledge are identified where future investigation may be fruitful with intent to inspire well-designed prospective studies with standardized treatment that focuses on improving oncological outcomes, reducing morbidity, or maintaining quality of life.

Identifiants

pubmed: 31060795
pii: S1078-1439(19)30142-5
doi: 10.1016/j.urolonc.2019.04.009
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

599-610

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Robert T Dess (RT)

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI. Electronic address: rdess@med.umich.edu.

Payal D Soni (PD)

Department of Radiation Oncology, Hunter Holmes McGuire VA Medical Center, Richmond, VA.

William C Jackson (WC)

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.

Alejandro Berlin (A)

Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Brett W Cox (BW)

Department of Radiation Medicine, Northwell Health, Hofstra Northwell School of Medicine, Hempstead, NY.

Shruti Jolly (S)

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.

Jason A Efstathiou (JA)

Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.

Felix Y Feng (FY)

Departments of Radiation Oncology, Urology and Medicine, University of California San Francisco, San Francisco, CA.

Amar U Kishan (AU)

Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA.

Bradley J Stish (BJ)

Department of Radiation Oncology, Mayo Clinic, Rochester, MN.

Thomas M Pisansky (TM)

Department of Radiation Oncology, Mayo Clinic, Rochester, MN.

Daniel E Spratt (DE)

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH